CLEVELAND, Jan. 10 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that through its research in the area of radiation protection, the Company has discovered a unique property of its Protectans 600 series, which has lead to a major breakthrough in the stem cell arena.

A single administration of CBLB612, the lead compound in the Protectans 600 series, resulted in a three-fold increase in the number of progenitor (originator) stem cells in mouse bone marrow within 24 hours after administration. Moreover, the number of these stem cells in peripheral blood was increased 10-fold within four days of administration. This research indicates that CBLB612 and other compounds in the 600 series are not only potent stimulators of bone marrow stem cells, but also cause their mobilization and proliferation throughout the blood. This discovery opens a new way to approach a broad spectrum of human diseases, some of which currently lack effective treatment.

Cleveland BioLabs's Protectans 600 series are modified factors of Mycoplasmas. Protectan CBLB612 has demonstrated both radiation protection and mitigation properties over a very broad time window of use. In animal experiments, Protectan CBLB612 has produced complete and sustained recovery of the hematopoietic (bone marrow/blood production) system following lethal doses of radiation.

Cleveland BioLabs President and Chief Executive Officer, Michael Fonstein, Ph.D., commented, "This discovery is a true breakthrough. Although it is still early in our research, it seems that we may have discovered a convenient source of adult stem cells, which can be used without permanent immuno- suppression. The potential applications for this technology are staggering. Producing a ready supply of hematopoietic stem cells for an individual without painful procedures, risk of contamination, or side effects would be tantamount to enabling the body to repair itself from any damage to its blood-forming system."

A report published by the National Institute of Health (NIH) division of the Department of Health and Human Services entitled "Regenerative Medicine 2006," notes that hematopoietic stem cells have been used clinically since 1959 and are used increasingly routinely for transplantations, albeit almost exclusively in a non-pure form. More than 40,000 transplants were performed annually worldwide by 1995. Currently, the main indications for bone marrow transplantation are either hematopoietic cancers (leukemias and lymphomas), or the use of high-dose chemotherapy for nonhematopoietic malignancies (cancers in other organs). Other indications include diseases that involve genetic or acquired bone marrow failure, such as aplastic anemia, thalassemia sickle cell anemia, and increasingly, autoimmune diseases.

A current therapeutic approach for increasing the amount of hematopoietic stem cells in blood, which is used independently or in conjunction with bone marrow or mobilized peripheral blood harvesting, is an injection of granulocyte-colony stimulating factor or G-CSF (Neupogen®, Granocyte®, Neulasta®). G-CSF is a human growth factor that works by inducing bone marrow to produce more white blood cells. In the Company's experiments with Protectan CBLB612, substantially higher yields of stem cells were generated in mobilized peripheral blood than by G-CSF.

The development of Cleveland BioLabs Protectans 600 series has been supported by a grant from the Defense Advanced Research Projects Agency of the Department of Defense (DARPA).

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often are proceeded by words such as "believes," "expects," "may," "anticipates," "plans," "intends," "assumes," "will" or similar expressions. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on September 8, 2006.

     The Global Consulting Group
     Rachel Levine
     T: (646) 284-9439